Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Feb 11;2(2):CD011255.
doi: 10.1002/14651858.CD011255.pub2.

Skin grafting and tissue replacement for treating foot ulcers in people with diabetes

Trientje B Santema  1 , Paul P C Poyck, Dirk T Ubbink
Affiliations
Meta-Analysis

Skin grafting and tissue replacement for treating foot ulcers in people with diabetes

Trientje B Santema et al. Cochrane Database Syst Rev. .

Abstract

Background: Foot ulceration is a major problem in people with diabetes and is the leading cause of hospitalisation and limb amputations. Skin grafts and tissue replacements can be used to reconstruct skin defects for people with diabetic foot ulcers in addition to providing them with standard care. Skin substitutes can consist of bioengineered or artificial skin, autografts (taken from the patient), allografts (taken from another person) or xenografts (taken from animals).

Objectives: To determine the benefits and harms of skin grafting and tissue replacement for treating foot ulcers in people with diabetes.

Search methods: In April 2015 we searched: The Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed Citations); Ovid EMBASE and EBSCO CINAHL. We also searched clinical trial registries to identify ongoing studies. We did not apply restrictions to language, date of publication or study setting.

Selection criteria: Randomised clinical trials (RCTs) of skin grafts or tissue replacements for treating foot ulcers in people with diabetes.

Data collection and analysis: Two review authors independently extracted data and assessed the quality of the included studies.

Main results: We included seventeen studies with a total of 1655 randomised participants in this review. Risk of bias was variable among studies. Blinding of participants, personnel and outcome assessment was not possible in most trials because of obvious differences between the treatments. The lack of a blinded outcome assessor may have caused detection bias when ulcer healing was assessed. However, possible detection bias is hard to prevent due to the nature of the skin replacement products we assessed, and the fact that they are easily recognisable. Strikingly, nearly all studies (15/17) reported industry involvement; at least one of the authors was connected to a commercial organisation or the study was funded by a commercial organisation. In addition, the funnel plot for assessing risk of bias appeared to be asymmetrical; suggesting that small studies with 'negative' results are less likely to be published.Thirteen of the studies included in this review compared a skin graft or tissue replacement with standard care. Four studies compared two grafts or tissue replacements with each other. When we pooled the results of all the individual studies, the skin grafts and tissue replacement products that were used in the trials increased the healing rate of foot ulcers in patients with diabetes compared to standard care (risk ratio (RR) 1.55, 95% confidence interval (CI) 1.30 to 1.85, low quality of evidence). However, the strength of effect was variable depending on the specific product that was used (e.g. EpiFix® RR 11.08, 95% CI 1.69 to 72.82 and OrCel® RR 1.75, 95% CI 0.61 to 5.05). Based on the four included studies that directly compared two products, no specific type of skin graft or tissue replacement showed a superior effect on ulcer healing over another type of skin graft or tissue replacement.Sixteen of the included studies reported on adverse events in various ways. No study reported a statistically significant difference in the occurrence of adverse events between the intervention and the control group.Only two of the included studies reported on total incidence of lower limb amputations. We found fewer amputations in the experimental group compared with the standard care group when we pooled the results of these two studies, although the absolute risk reduction for amputation was small (RR 0.43, 95% CI 0.23 to 0.81; risk difference (RD) -0.06, 95% CI -0.10 to -0.01, very low quality of evidence).

Authors' conclusions: Based on the studies included in this review, the overall therapeutic effect of skin grafts and tissue replacements used in conjunction with standard care shows an increase in the healing rate of foot ulcers and slightly fewer amputations in people with diabetes compared with standard care alone. However, the data available to us was insufficient for us to draw conclusions on the effectiveness of different types of skin grafts or tissue replacement therapies. In addition, evidence of long term effectiveness is lacking and cost-effectiveness is uncertain.

PubMed Disclaimer

Conflict of interest statement

  1. Katrien Santema: none known.

  2. Paul Poyck: none known.

  3. Dirk Ubbink: none known.

Figures

1
1
Study flow diagram of the number of records identified, included and excluded, and the reasons for exclusion
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
3
3
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
4
4
Funnel plot of comparison: 1 Skin grafts or tissue replacements compared with standard care, outcome: 1.1 Incidence of complete closure of the foot ulcer.
1.1
1.1. Analysis
Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 1 Incidence of complete closure of the foot ulcer.
1.2
1.2. Analysis
Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 2 Incidence of compete closure of the foot ulcer ‐ sensitivity analysis.
1.3
1.3. Analysis
Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 3 Incidence of lower limb amputations.
1.4
1.4. Analysis
Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 4 Ulcer recurrence.
1.5
1.5. Analysis
Comparison 1 Skin grafts or tissue replacements compared with standard care, Outcome 5 Incidence of infection.
2.1
2.1. Analysis
Comparison 2 Meshed skin graft compared with split‐skin graft, Outcome 1 Incidence of complete closure of the foot ulcer.
3.1
3.1. Analysis
Comparison 3 Dermagraft® compared with OASIS®, Outcome 1 Incidence of complete closure of the foot ulcer.
4.1
4.1. Analysis
Comparison 4 Apligraf® compared with TheraSkin®, Outcome 1 Incidence of complete closure of the foot ulcer.
5.1
5.1. Analysis
Comparison 5 Dermagraft® compared with TheraSkin®, Outcome 1 Incidence of complete closure of the foot ulcer.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD011255

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Brigido 2006 {published data only}
    1. Brigido SA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16‐week pilot study. International Wound Journal 2006;3(3):181‐7. - PMC - PubMed
Caravaggi 2003 {published data only}
    1. Caravaggi C, Giglio R, Pritelli C, Sommaria M, Dalla Noce S, et al. HYAFF 11‐based autologous dermal and epidermal grafts in the treatment of noninfected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. Diabetes Care 2003;26(10):2853‐9. - PubMed
DiDomenico 2011 {published data only}
    1. DiDomenico L, Emch KJ, Landsman AR, Landsman A. A prospective comparison of diabetic foot ulcers treated with either a cryopreserved skin allograft or a bioengineered skin substitute. Wounds 2011;23(7):184‐9. - PubMed
Edmonds 2009 {published data only}
    1. Edmonds M, the European and Australian Apligraf Diabetic Foot Ulcer Study Group. Apligraf in the treatment of neuropathic diabetic foot ulcers. The International Journal of Lower Extremity Wounds 2009;8(1):11‐8. - PubMed
Gentzkow 1996 {published data only}
    1. Gentzkow GD, Iwasaki SD, Hershon KS, Mengel M, Prendergast JJ, Ricotta JJ, et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996;19(4):350‐4. - PubMed
Landsman 2008 {published data only}
    1. Gilligan AM, Waycaster CR, Landsman AL. Wound closure in patients with DFU: a cost‐effectiveness analysis of two cellular/tissue‐derived products. Journal of Wound Care 2015;23(3):149‐56. - PubMed
    1. Landsman A, Roukis TS, DeFronzo DJ, Agnew P, Petranto RD, Suprenant M. Living cells or collegen matrix: which is more beneficial in the treatment of diabetic foot ulcers. Wounds 2008;20(5):111‐6. - PubMed
Lipkin 2003 {published data only}
    1. Lipkin S, Chaikof E, Isseroff Z, Silverstein P. Effectiveness of bilayered cellular matrix in healing of neuropathic diabetic foot ulcers. Wounds 2003;15(7):230‐6.
Marston 2003 {published data only}
    1. Frykberg RG, Marston WA, Cardinal M. The incidence of lower‐extremity amputation and bone resection in diabetic foot ulcer patients treated with a human fibroblast‐derived dermal substitute. Advances in Skin & Wound Care 2015;28:17‐20. - PubMed
    1. Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003;26(6):1701‐5. - PubMed
Naughton 1997 {published data only}
    1. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcer. Artificial Organs 1997;21(11):1203‐10. - PubMed
    1. Pollak RA, Edington H, Jensen JL, Kroeker RO, Gentzkow GD. A human dermal replacement for the treatment of diabetic foot ulcers. Wounds 1997;9:175‐83.
Puttirutvong 2004 {published data only}
    1. Puttirutvong P. Meshed skin graft versus split thickness skin graft in diabetic ulcer coverage. Journal of the Medical Association of Thailand 2004;87(1):66‐72. - PubMed
Reyzelman 2009 {published data only}
    1. Reyzelman A, Crews RT, Moore JC, Moore L, Mukker JS, Offutt S, et al. Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. International Wound Journal 2009;6(3):196‐208. - PMC - PubMed
Sanders 2014 {published data only}
    1. Sanders L, Landsman AD, Landsman A, Keller N, Cook J, Hopson M. A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft. Ostomy Wound Management 2014;60(8):26‐38. - PubMed
Uccioli 2011 {published data only}
    1. Uccioli L, Giurato L, Ruotolo V, Ciavarella A, Grimaldi MS, Piaggesi A, et al. Two‐step autologous grafting using HYAFF scaffolds in treating difficult diabetic foot ulcers: results of a multicenter, randomized controlled clinical trial with long‐term follow‐up. The International Journal of Lower Extremity Wounds 2011;10(2):80‐5. - PubMed
Veves 2001 {published data only}
    1. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001;24(2):290‐5. - PubMed
You 2012 {published data only}
    1. You HJ, Han SK, Lee, JW, Chang H. Treatment of diabetic foot ulcers using cultured allogeneic keratinocytes‐‐a pilot study. Wound Repair and Regeneration 2012;20(4):491‐9. - PubMed
You 2014 {published data only}
    1. You HJ, Han SK, Rhie JW. Randomised controlled clinical trial for autologous fibroblast‐hyaluronic acid complex in treating diabetic foot ulcers. Journal of Wound Care 2014;23(11):521‐30. - PubMed
Zelen 2013 {published data only}
    1. Zelen CM, Serena TE, Denoziere G, Fetterolf DE. A prospective, randomised comparative parallel study amniotic membrane wound graft in the management of diabetic foot ulcers. International Wound Journal 2013;10(5):502‐7. - PMC - PubMed

References to studies excluded from this review

Hanft 2002 {published data only}
    1. Hanft JR, Suprenant MS. Healing of chronic foot ulcer in diabetic patients treated with a human fibroblast‐derived dermis. The Journal of Foot & Ankle Surgery 2002;41(5):291‐9. - PubMed
Moustafa 2007 {published data only}
    1. Moustafa M, Bullock AJ, Creagh FM, Heller S, Jeffcoate W, Game F, et al. Randomized, controlled, single‐blind study on use of autologous keratinocytes on a transfer dressing to treat nonhealing diabetic ulcers. Regenerative medicine 2007;2(6):887‐902. - PubMed
Niezgoda 2005 {published data only}
    1. Niezgoda JA, Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Advances in Skin & Wound Care 2005;18(5 Pt 1):258‐66. - PubMed
Pham 1999 {published data only}
    1. Pham HT, Rosenblum BI, Lyons TE, Giueini JM, Charzan JS, Habershaw GM, et al. Evaluation of a human skin equivalent for the treatment of diabetic foot ulcers in a prospective, randomized, clinical trial. Wounds 1999;11(4):1044‐6.
Sams 2002 {published data only}
    1. Sams HH, Chen J, King LE. Graftskin treatment of difficult to heal diabetic foot ulcers: one center's experience. Dermatologic Surgery 2002;28:698‐703. - PubMed

References to studies awaiting assessment

Lavery 2014 {published data only}
    1. Lavery LA, Fulmer J, Shebetka KA, Regulski M, Vayser D, Fried D, et al. The Grafix Diabetic Foot Ulcer Study Group. The efficacy and safety of Grafix® for the treatment of chronic diabetic foot ulcers: results of a multi‐centre, controlled, randomised, blinded, clinical trial. International Wound Journal 2014;11:554‐60. [DOI: 10.1111/iwj.12329] - DOI - PMC - PubMed

References to ongoing studies

NCT01693133 {published data only}
    1. NCT01693133. Trial of Dehydrated Human Amnion/Chorion Membrane (dHACM) In the Management of Diabetic Foot Ulcers. https://www.clinicaltrials.gov/ct2/show/NCT01693133 (accessed 14 August 2015).
NCT02070835 {published data only}
    1. NCT02070835. Study of ReCell® Treating for Diabetic Foot Ulcers. https://clinicaltrials.gov/ct2/show/NCT02070835 (accessed 14 August 2015).
NCT02120755 {published data only}
    1. NCT02120755. A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds. https://clinicaltrials.gov/ct2/show/NCT02120755 (accessed 14 August 2015).
NCT02331147 {published data only}
    1. NCT02331147. Allogenic Dermis Versus Standard Care in the Management of Diabetic Foot Ulcers. https://clinicaltrials.gov/ct2/show/NCT02331147 (accessed 14 August 2015).
NCT02399826 {published data only}
    1. NCT02399826. Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers. https://clinicaltrials.gov/ct2/show/NCT02399826 (accessed 14 August 2015).

Additional references

Abbot 2005
    1. Abbott CA, Garrow AP, Carrington AL, Morris J, Ross ER, Boulton AJ. Foot ulcer risk is lower in South Asian and African‐Caribbean compared to European diabetic patients in the UK: the North‐West Diabetes Footcare Study. Diabetes Care 2005;28(8):1869–75. - PubMed
Apelqvist 1995
    1. Apelqvist J, Ragnarson‐Tennvall G, Larsson J, Persson U. Long‐term costs for foot ulcers in diabetic patients in a multidisciplinary setting. Foot & Ankle International 1995;16(7):388‐94. - PubMed
Apelqvist 1999
    1. Apelqvist J, Larsson J. What is the most effective way to reduce incidence of amputation in the diabetic foot?. Diabetes/Metabolism Research and Reviews 1999;16 Suppl 1:75‐83. - PubMed
Bergin 2006
    1. Bergin S, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD005082.pub2] - DOI - PubMed
Blozik 2008
    1. Blozik E, Scherer M. Skin replacement therapies for diabetic foot ulcers: systematic review and meta‐analysis. Diabetes Care 2008;41(4):693‐4. - PubMed
Boulton 2008
    1. Boulton AJ. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes/Metabolism Research and Reviews 2008;24 Suppl 1:3‐6. - PubMed
Cruciani 2013
    1. Cruciani M, Lipsky BA, Mengoli C, Lalla F. Granulocyte‐colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD006810.pub3] - DOI - PMC - PubMed
Danaei 2011
    1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country‐years and 2·7 million participants. The Lancet 2011;378(9785):31‐40. - PubMed
Dumville 2013a
    1. Dumville JC, O'Meara S, Deshpande S, Speak K. Alginate dressings for healing diabetic foot ulcers. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD009110.pub3] - DOI - PMC - PubMed
Dumville 2013b
    1. Dumville JC, Deshpande S, O'Meara S, Speak K. Foam dressings for healing diabetic foot ulcers. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD009111.pub3] - DOI - PMC - PubMed
Dumville 2013c
    1. Dumville JC, O'Meara S, Deshpande S, Speak K. Hydrogel dressings for healing diabetic foot ulcers. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD009101.pub3] - DOI - PMC - PubMed
Dumville 2013d
    1. Dumville JC, Deshpande S, O'Meara S, Speak K. Hydrocolloid dressings for healing diabetic foot ulcers. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD009099.pub3] - DOI - PMC - PubMed
Edwards 2010
    1. Edwards J, Stapley S. Debridement of diabetic foot ulcers. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD003556.pub2] - DOI - PMC - PubMed
Falanga 1998
    1. Falanga V, Margolis D, Alvarez O, Auletta M, Maggiacomo F, Altman M, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Archives of Dermatology 1998;134:293‐300. - PubMed
Falanga 2005
    1. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005;366(9498):1736‐43. - PubMed
Fernando 2013
    1. Fernando ME, Seneviratne RM, Cunningham M, Lazzarini PA, Sangla KS, Mong Tang Y, et al. Intensive versus conventional glycaemic control for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010764] - DOI - PMC - PubMed
Frykberg 2015
    1. Frykberg RG, Marston WA, Cardinal M. The incidence of lower‐extremity amputation and bone resection in diabetic foot ulcer patients treated with a human fibroblast‐derived dermal substitute. Advances in Skin & Wound Care 2015;28(1):17‐20. - PubMed
Game 2012
    1. Game F. Choosing life or limb. Improving survival in the multi‐complex diabetic foot patient. Diabetes/Metabolism Research and Reviews 2012;28 Suppl 1:97‐100. - PubMed
Gilligan 2015
    1. Gilligan AM, Waycaster CR, Landsman AL. Wound closure in patients with DFU: a cost‐effectiveness analysis of two cellular/tissue‐derived products. Journal of Wound Care 2015;24(3):149‐56. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011a
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins 2011b
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hinchliffe 2012
    1. Hinchliffe RJ, Andros G, Apelqvist J, Bakker K, Friederichs S, Lammer J, et al. A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes/Metabolism Research and Reviews 2012;28 Suppl 1:179‐217. - PubMed
Izumi 2009
    1. Izumi Y, Satterfield K, Lee S, Harkless LB, Lavery LA. Mortality of first‐time amputees in diabetics: a 10‐year observation. Diabetes Research and Clinical Practice 2009;83:126‐31. - PubMed
Jeffcoate 2003
    1. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. The Lancet 2003;261:1545‐51. - PubMed
Jeffcoate 2004
    1. Jeffcoate WJ, Houtum WH. Amputation as a marker of the quality of foot care in diabetes. Diabetologia 2004;47:2051‐8. - PubMed
Jull 2013
    1. Jull AB, Walker N, Deshpande S. Honey as a topical treatment for wounds. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD005083.pub3] - DOI - PubMed
Kranke 2015
    1. Kranke P, Bennett MH, Martyn‐St James M, Schnabel A, Debus SE, Weibel S. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD004123.pub3] - DOI - PMC - PubMed
Langer 2009
    1. Langer A, Rogowski W. Systematic review of economic evaluations of human cell‐derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Services Research 2009;9:115. - PMC - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Levin 1998
    1. Levin M. Prevention and treatment of diabetic foot ulcers. Journal of Wound Ostomy and Continence Nursing 1998;21:129‐46. - PubMed
Lewis 2013
    1. Lewis J, Lipp A. Pressure‐relieving interventions for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD002302.pub2] - DOI - PMC - PubMed
Margolis 1999
    1. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta‐analysis. Diabetes Care 1999;22:692‐5. - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA Statement. BMJ 2009;339:2535. - PMC - PubMed
Nabuurs‐Franssen 2005
    1. Nabuurs‐Franssen MH, Huijberts MS, Nieuwenhuijzen Kruseman AC, Willems J, Schaper NC. Health‐related quality of life of diabetic foot ulcer patients and their caregivers. Diabetologia 2005;48(9):1906‐10. - PubMed
Pham 2000
    1. Pham HT, Rich J, Veves A. Wound healing in diabetic foot ulceration. A review and commentary. Wounds 2000;12(4):79‐82.
Quattrini 2008
    1. Quattrini C, Jeziorska M, Boulton AJ, Malik RA. Reduced vascular endothelial growth factor expression and intra‐epidermal nerve fiber loss in human diabetic neuropathy. Diabetes Care 2008;31:140‐5. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Schaper 2004
    1. Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes/Metabolism Research and Reviews 2004;20 Suppl 1:S90‐5. - PubMed
Schulz 2010
    1. Schultz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332. - PMC - PubMed
Schunemann 2011a
    1. Schunemann 2011a Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results, 'Summary of findings' tables. In: Higgins JPT. Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Schunemann 2011b
    1. Schünemann HJ, Oxman AD, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results, drawing conclusions. In: Higgins JPT. Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
SIGN 2014
    1. Scottish Intercollegiate Guidelines Network (SIGN). Search filters. http://www.sign.ac.uk/methodology/filters.html#random (accessed April 2014).
Singh 2005
    1. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005;293:217‐28. - PubMed
Skoutas 2009
    1. Skoutas D, Papanas N, Georgiadis GS, Zervas V, Manes C, Maltezos E, et al. Risk factors for ipsilateral reamputation in patients with diabetic foot lesions. The International Journal of Lower Extremity Wounds 2009;8:69‐74. - PubMed
Stockl 2004
    1. Stockl K, Vanderplas A, Tafesse E, Chang E. Costs of lower‐extremity ulcers among patients with diabetes. Diabetes Care 2004;27:2129–34. - PubMed
Stoekenbroek 2014
    1. Stoekenbroek RM, Santema TB, Legemate DA, Ubbink DT, Brink A, Koelemay MJ. Hyperbaric oxygen for the treatment of diabetic foot ulcers: a systematic review. European Journal of Vascular and Endovascular Surgery 2014;47(6):647‐55. - PubMed
Szabo 2009
    1. Szabo C. Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. British Journal of Pharmacology 2009;156:713‐27. - PMC - PubMed
Teng 2010
    1. Teng YJ, Li YP, Wang JW, Yang KH, Zhang YC, Wang YJ, et al. Bioengineered skin in diabetic foot ulcers. Diabetes, Obesity & Metabolism 2010;12(4):307‐15. - PubMed
Valensi 2005
    1. Valensi P, Girod I, Baron F, Moreau‐Defarges T, Guillon P. Quality of life and clinical correlates in patients with diabetic foot ulcers. Diabetes & Metabolism 2005;31:263‐71. - PubMed

References to other published versions of this review

Santema 2014
    1. Santema TB, Poyck PPC, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD011255] - DOI - PMC - PubMed

Publication types

MeSH terms